Live Breaking News & Updates on First Light Asset Management|Page 5

Stay updated with breaking news from First light asset management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $21.43 Average PT from Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock […] ....

Cyrus Harmon , Analyst Recommendations For Olema Pharmaceuticals , Goldman Sachs Group , Dimensional Fund Advisors , Swiss National Bank , Securities Exchange Commission , Jump Financial , Perceptive Advisors , First Light Asset Management , Olema Pharmaceuticals Price Performance , Olema Pharmaceuticals Inc , Olema Pharmaceuticals , News Ratings For Olema Pharmaceuticals Daily , Get Free Report , One Financial , Director Cyrus Harmon , Exchange Commission , Light Asset Management , Fund Advisors , Get Free , Olema Pharmaceuticals Daily , Nasdaq Olma ,

Joint (NASDAQ:JYNT) Stock Passes Above Fifty Day Moving Average of $11.48

Shares of The Joint Corp. (NASDAQ:JYNT – Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $11.48 and traded as high as $12.26. Joint shares last traded at $12.02, with a volume of 51,983 shares. Wall Street Analysts Forecast Growth […] ....

United States , Cubist Systematic Strategies , First Light Asset Management , Company Profile , Renaissance Technologies , Asset Management Americas Inc , Thrivent Financial For Lutherans , Get Free Report , Management Americas , Systematic Strategies , Light Asset Management , Corporate Clinics , Joint Daily , Nasdaq Jynt ,

Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $204.00 price target on the stock, up from their prior price target of $178.00. Other research analysts have also recently issued reports about the stock. William Blair […] ....

United States , Suma Krishnan , Stifel Nicolaus , William Blair , Kathryn Romano , Krystal Biotech Company Profile , First Light Asset Management , Krystal Biotech Inc , Jennison Associates , Blackrock Inc , Securities Exchange Commission , Vanguard Group Inc , Krystal Biotech , Free Report , Biotech Trading Down , Get Free Report , Exchange Commission , Street Corp , Light Asset Management , Krystal Biotech Daily , Nasdaq Krys , Reiterated Rating ,

Paragon 28 (NYSE:FNA) Trading Up 4.7%

Shares of Paragon 28, Inc. (NYSE:FNA – Get Free Report) were up 4.7% on Tuesday . The company traded as high as $10.76 and last traded at $10.60. Approximately 216,022 shares traded hands during trading, a decline of 59% from the average daily volume of 530,748 shares. The stock had previously closed at $10.12. Wall […] ....

United States , Piper Sandler , Albert Dacosta , First Light Asset Management , Needham Company , Blackrock Inc , Vanguard Group Inc , Company Profile , Get Free Report , Light Asset Management , Vanguard Group ,